Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
about
Therapeutic targeting of cancers with loss of PTEN function.Endothelial Cell mTOR Complex-2 Regulates Sprouting AngiogenesisTAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast CancerCombined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathwayThe PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgraftsA critical role for the mTORC2 pathway in lung fibrosis.Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus SpeciesmTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancerMLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas.mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy.A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs
P2860
Q27852764-A5CD2E80-E335-4998-BF41-3B340D8D559DQ28547399-DBD6E0C4-B850-4A69-9ABE-AB21488B33C1Q33429430-3B6032EE-A1B1-4371-9C23-1DB24CF05251Q33442621-4F550CBE-B51A-44BF-92B5-AD30022DA465Q33739184-346692E4-8594-45BE-9E47-11645FF0FDCDQ34080323-8AE0CCA4-1729-4314-B329-1BEFDDFB362CQ34135475-E8F817C4-F086-474E-B02D-695A8F6309E3Q34465116-02490261-6188-4F7B-A17A-0100FAE5E669Q34995919-9ED0D0C1-B3FF-4714-AECA-4A1C8C793A09Q35053837-D9E8C24E-E3CF-4C64-9012-71BAB81F79D3Q35096201-DDCE39D4-CE14-457D-AB06-8863D0B0F109Q35151333-E93A8387-7DE6-4B3F-AA16-CAAC03102A8FQ35194746-38056827-09D1-4DC6-8025-0F32CE908A1DQ35232857-58DD0661-4E84-4257-9DA2-673960FDD964Q36111029-AAFEAEFA-9965-4D47-92BE-C4A8A96BE339Q36854062-D417312A-2DBC-441F-9D31-2FF4D2C7372DQ36916277-1E90B56A-ACF7-4AE4-8739-742A464C5B46Q36933432-57C9E55C-D37A-4554-BA35-FC3C820927A3Q37295289-A3C76C83-397E-4586-8237-DD19E8A27159Q37688200-DBB5BDC1-F64D-45F4-8268-5595F4639255Q38705818-787B139F-3E90-4465-A729-0C0C02B57AF8Q38743320-DFB27256-570B-492E-B94E-D30C9216AC6CQ39023175-B0BA9C42-B0F7-4607-AB67-DB339CA9CB11Q40058161-F3722830-56B9-4F32-B80E-8CC9DB9EC31EQ41710033-CFBC7A34-66AF-4212-81F4-B365C6D7DE11Q47577143-FEE3BAF5-87A3-422D-B796-DEACF507C49AQ52092512-58B0E9FE-37C3-4501-8381-E68ABD868C76Q55111944-700B54A6-5ADE-41B4-B0AC-5F6719C82902Q55381339-73E25804-EC8F-4B85-8A7E-9A6F8B370599Q58764425-DD4B390A-BF28-4931-8425-9360F10F26FB
P2860
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Investigational drug MLN0128, ...... reast cancer xenograft models.
@en
Investigational drug MLN0128, ...... reast cancer xenograft models.
@nl
type
label
Investigational drug MLN0128, ...... reast cancer xenograft models.
@en
Investigational drug MLN0128, ...... reast cancer xenograft models.
@nl
prefLabel
Investigational drug MLN0128, ...... reast cancer xenograft models.
@en
Investigational drug MLN0128, ...... reast cancer xenograft models.
@nl
P2093
P2860
P1476
Investigational drug MLN0128, ...... reast cancer xenograft models.
@en
P2093
Christian Rommel
George W Sledge
Kerry L Sanders
Rachel A Toroni
Rutika Mehta
Sunil Badve
Yesim Gökmen-Polar
P2860
P2888
P304
P356
10.1007/S10549-012-2298-8
P407
P577
2012-10-21T00:00:00Z